ABSTRACT
The skin at the site of HSV-2 reactivation is enriched for HSV-2-specific T cells. To evaluate whether an immunotherapeutic vaccine could elicit skin-based memory T cells, we studied skin biopsies and HSV-2-reactive CD4+ T cells from peripheral blood mononuclear cells (PBMCs) by T cell receptor β (TRB) sequencing before and after vaccination with a replication-incompetent whole virus HSV-2 vaccine candidate (HSV529). The representation of HSV-2-reactive CD4+ TRB sequences from PBMCs in the skin TRB repertoire increased after the first vaccine dose. We found sustained expansion after vaccination of unique, skin-based T-cell clonotypes that were not detected in HSV-2-reactive CD4+ T cells isolated from PBMCs. In one participant a switch in immunodominance occurred with the emergence of a T cell receptor (TCR) αβ pair after vaccination that was not detected in blood. This TCRαβ was shown to be HSV-2-reactive by expression of a synthetic TCR in a Jurkat-based NR4A1 reporter system. The skin in areas of HSV-2 reactivation possesses an oligoclonal TRB repertoire that is distinct from the circulation. Defining the influence of therapeutic vaccination on the HSV-2-specific TRB repertoire requires tissue-based evaluation.
Competing Interest Statement
JT and SG are current employees of Sanofi Pasteur. ASM is a consultant for Cero and AiCuris. CJ has received institutional research funding to the University of Washington from Sanofi, Genocea, Vical and Gilead and is a consultant to AbbVie and Gilead. DMK has received research funding from Sanofi Pasteur, Immune Design Corporation, and Admedus Immunotherapy concerning herpes vaccines, has served as a consultant to Biomedical Research Models on herpes vaccines, and is a coinventor on patents owned by the University of Washington involving herpes vaccines. LC is on the scientific advisory board for and holds stock (<1% of the company) in Immune Design Corp and is a coinventor listed on several patents involving potential HSV vaccine development. KJL has received salary support from Sanofi and Admedus Immunotherapy and is coinventor on patents owned by the University of Washington involving herpes vaccines.
Clinical Trial
NCT02571166
Funding Statement
The authors would like to acknowledge funding from the NIH to researchers for salary and research support including K08 AI148588 (ESF), U19 AI113173 (ESF, ASM), P01 AI030731 (CJ, ASM, JZ, DMK, LC), R01 AI042528 (JZ, LC), R01 AI134878 (JZ, LC), P30 CA015704 (core facilities). JT and SG are current employees of Sanofi Pasteur. Sanofi Pasteur provided funding to FHCRC for this investigator-initiated trial. The funder was not involved in the study design, data collection, data analysis, decision to publish, or manuscript preparation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Participants provided informed consent to participate in the trial. The University of Washington Human Subjects Division approved the study procedures. The trial was monitored by a Data Safety Monitoring Board. The trial was registered on clinicaltrials.gov, NCT02571166.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
ClinicalTrials.gov Identifier: NCT02571166
Competing Interests:
JT and SG are current employees of Sanofi Pasteur.
ASM is a consultant for Cero and AiCuris.
CJ has received institutional research funding to the University of Washington from Sanofi, Genocea, Vical and Gilead and is a consultant to AbbVie and Gilead.
DMK has received research funding from Sanofi Pasteur, Immune Design Corporation, and Admedus Immunotherapy concerning herpes vaccines, has served as a consultant to Biomedical Research Models on herpes vaccines, and is a coinventor on patents owned by the University of Washington involving herpes vaccines.
LC is on the scientific advisory board for and holds stock (<1% of the company) in Immune Design Corp and is a coinventor listed on several patents involving potential HSV vaccine development.
KJL has received salary support from Sanofi and Admedus Immunotherapy and is coinventor on patents owned by the University of Washington involving herpes vaccines
Revised manuscript, figures, and data analysis
